Targeted Immunotherapy


power in specificity

targeted next-generation cytokines

IL2 - the first immunotherapy

The promise of cytokine therapy

The FDA approved high-dose interleukin 2 for the treatment of advanced cancer in the 1990’s, making it the first immunotherapy. Administration of systemic high-dose IL2 improves the tumor immune response via activation of the cancer-killing natural killer cells (NK) and CD8+ T cell. High-dose IL2 results reverses tumor suppression of the immune system and profoundly activates these cells.

Up to 9% of renal cell carcinoma and melanoma patients have a durable, long-lasting curative response after IL2 therapy.

Decades of experience with high-dose IL2 indicate superiority to modern immuno-oncology therapeutics. Unfortunately, the use high-dose IL2 therapy is limited due to off-target effects on the vasculature and T regulatory cells. Stimulation of these cells results in significant adverse effects in patients.

Courier targeting technology

first-in-class cytokine therapy

IL2-family therapeutics hit a broad range of tumor-killing and toxicity-causing cells. These off-target effects limit the widespread use of these therapeutics and the overall effectiveness of the therapy.

CT101 is a rationally designed targeted IL2R agonist targeted directly to the cancer-killing immune cells (NK and CD8 T cells). Systemic activation of these cells enables them to seek out and destroy cancer throughout the body.

direct immune targeting

an immune focused platform

Courier's targeting technology can be extended to a broad number of immunomodulatory drugs. We are actively developing a variety of therapeutics which take an immune-first approach.

Nature Communications

Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy

Ghasemi R, Lazear E, Wang X, Arefanian S, Zheleznyak A, Carreno BM, Higashikubo R, Gelman AE, Kreisel D, Fremont DH, Krupnick AS